Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?

Published by: Decision Resources

Published: Mar. 18, 2008 - 39 Pages

Table of Contents

Executive Summary

Strategic Considerations

Trends and Their Implications for Stakeholders

Evolving Biologics Market

Alzheimer’s Disease and Anti-Amyloid Antibodies

Elan/Wyeth’s AAB-001 (Bapineuzumab)

MAbs in Early-Stage Clinical Development for Alzheimer’s Disease

Anti-Integrin Antibodies

Biogen Idec/Elan’s Tysabri (Natalizumab)

Anti-Integrin Antibodies in Early-Stage Clinical Development

Biogen Idec/PDL BioPharma’s M-200 (Volociximab)

Johnson & Johnson/Centocor/Medarex’s CNTO-95

Millennium’s MLN-0002

Selective T-Cell Co-Stimulation Antagonists

Superagonist Debacle

Bristol-Myers Squibb’s Orencia (Abatacept)

Three Phase III Contenders

Bristol-Myers Squibb’s LEA29Y (Belatacept)

Medarex/Bristol-Myers Squibb’s MDX-010 (Ipilimumab)

Pfi zer’s CP-675,206 (Tremelimumab)

Complement and Complement Receptor Antibodies

HIV Antibody Therapies

Blocking Immune Cell Migration to Infl ammation Sites

Cytotoxicity-Enhanced CCR4 Antibody

B-Cell-Targeted Therapies: Anti-CD20 Antibodies

Biogen Idec/Genentech/Roche/Chugai/Zenyaku’s Rituxan/MabThera (Rituximab)

Anti-CD20 Antibodies in Clinical Development

Biogen Idec/Genentech/Roche’s R-1594/PRO-70769 (Ocrelizumab)

GlaxoSmithKline/Genmab’s HuMax-CD20 (Ofatumumab)

Immunomedics’ IMMU-106 (Veltuzumab)

Next-Generation Engineered Antibodies

Radioimmunotherapy

T-Cell-Targeted Therapies

Anti-CD3 Antibodies

Agents in Development for Recent-Onset Type 1 Diabetes

Agents in Development for Infl ammatory Bowel Diseases

CD4-Targeting Antibodies

Novel Interleukin-6 Receptor Antagonist Class

Tumor Necrosis Factor-Alpha Inhibitors

EGFR-Targeted Therapies

Bristol-Myers Squibb/ImClone Systems /Merck Serono’s Erbitux (Cetuximab)

Amgen’s Vectibix (Panitumumab)

EGFR Antagonists in Clinical Development

Oncoscience/YM Bioscience/Daiichi Sankyo’s TheraCIM h-R3/Theraloc (Nimotuzumab)

Genmab’s HuMax-EGFR (Zalutumumab)

Merck Serono/Takeda’s EMD-72000 (Matuzumab)

Bristol-Myers Squibb/ImClone Systems’ IMC-11F8

Abstract

Monoclonal antibodies (MAbs) are very hot commodities in today’s pharmaceutical marketplace, and in recent years, the growth in the number of MAbs under development has far outpaced the growth of other types of drugs. With expert insight from our Decision Resources analysts, we look at approximately 70 MAbs in latestage development, identify promising MAbs, and discuss four developing trends in MAb markets.

Get the Answers You Need to Shape Your Strategy

• Monoclonal antibodies are one of the fastest growing segments of the pharmaceutical industry. Will the intense competition in this market lead to saturation in some segments? Which classes could get crowded if new MAbs in development successfully enter the market?
• MAbs are highly sought after by the pharmaceutical industry to fill sparse pipelines with new biologics. Which companies are looking to ramp up their MAb production? Who will be the key players in this arena going forward?
• MAb markets are becoming complex, and companies with emerging MAbs need to carefully consider how best to position their products. Which factors will be the most important to ensuring market success for new MAbs? What strategies are companies pursuing?

Scope

• A review of the evolving biologics market: the role of MAbs, sales figures, market leaders.
• MAbs in development in ten different drug classes: their stage of development and the companies developing them.
• Four interesting trends in MAb markets: developments that are adding new layers of complexity to the MAb landscape, trends to be carefully consideredwhen entering or competing in today’s evolving MAb markets, implications for stakeholders.
• Expert insight from Decision Resources analysts: comparison of the relative merits of MAbs now in development, by the following analysts:

- Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Clair Gricks, Ph.D., analyst, Onkos
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum, Pharmacoeconomics, Pricing, and Reimbursement
- Bethany A. Kiernan, Ph.D., analyst, Cognos
- Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
- Nitasha Manchanda, Ph.D., analyst, Cognos
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy Markets and Emerging Technologies
- Mohamed Muhsin, M.Sc., analyst, Onkos
- Alice von Loesecke, Ph.D., senior director, New Products

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.